Pfizer

News

ViiV ownership shifts as Pfizer sells its stake

Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.

News

Madrigal eyes combination MASH therapy with Pfizer deal

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.

News

Plaintiff wording on placeholder on court desk

Bayer's Monsanto sues mRNA COVID-19 vaccine makers

Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

ViiV ownership shifts as Pfizer sells its stake

Madrigal eyes combination MASH therapy with Pfizer deal

Bayer's Monsanto sues mRNA COVID-19 vaccine makers

As year-end nears, pharma groups plump up their pipelines

Padcev/Keytruda scores again in early bladder cancer

Pfizer makes first-line case for Tukysa in breast cancer

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks